- Mumbai: Tata Sons, Tata Industries and Rallis India announced today that they, along with individual shareholders of Advinus Therapeutics (“Advinus”), have signed a definitive agreement with Eurofins Scientific (“Eurofins”) for Eurofins to acquire Advinus. The transaction is expected to close in the next several weeks, subject to the fulfilment of customary closing conditions. Advinus’ expertise complements Eurofins contract research, development and manufacturing (CDMO) capabilities.
Advinus is a leading preclinical contract research company for Safety Assessment, CMC Services, DMPK and Analytical R&D Services.
With over 10 years of GLP compliance and certification, Advinus serves diverse industries such as Biotech, Pharmaceuticals, Biologics, Agrochemicals, Nutraceuticals and Cosmetics. Advinus has submitted over 50 end-to-end investigational new drug applications (INDs) to global regulators such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency in the UK (MHRA) and Health Canada among others. Located in Bangalore, India, Advinus operates a state-of-the art 20,000 m2 facility.
KRS Jamwal, chairman of Advinus and executive director of Tata Industries, said, “Advinus has developed significant promise under Tata parenting, and will now realise its full potential joining the Eurofins family of laboratories. We are confident that with access to Eurofins’ global network and technical competencies, Advinus will be able to rapidly expand its analytical portfolio and services to benefit all its existing and future clients.”
Rajiv Malik, chief executive officer of Advinus, said, “Advinus has substantial capabilities that are in synergy with Eurofins and provide us with additional opportunities to grow the Company. We are very excited about becoming a part of the Eurofins family.”